Celltrion Pharm Inc banner
C

Celltrion Pharm Inc
KOSDAQ:068760

Watchlist Manager
Celltrion Pharm Inc
KOSDAQ:068760
Watchlist
Price: 56 100 KRW -2.77%
Market Cap: ₩2.5T

EV/GP

15.5
Current
31%
Cheaper
vs 3-y average of 22.5

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
15.5
=
Enterprise Value
₩2.6T
/
Gross Profit
₩163.8B

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
15.5
=
Enterprise Value
₩2.6T
/
Gross Profit
₩163.8B

Valuation Scenarios

Celltrion Pharm Inc is trading below its 3-year average

If EV/GP returns to its 3-Year Average (22.5), the stock would be worth ₩81 732.21 (46% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-75%
Maximum Upside
+70%
Average Downside
6%
Scenario EV/GP Value Implied Price Upside/Downside
Current Multiple 15.5 ₩56 100
0%
3-Year Average 22.5 ₩81 732.21
+46%
5-Year Average 26.3 ₩95 288.84
+70%
Industry Average 3.8 ₩13 837.93
-75%
Country Average 5.4 ₩19 620.21
-65%

Forward EV/GP
Today’s price vs future gross profit

Not enough data available to calculate forward EV/GP

Peer Comparison

All Multiples
EV/GP
P/E
All Countries
Close
Market Cap EV/GP P/E
KR
Celltrion Pharm Inc
KOSDAQ:068760
2.5T KRW 15.5 64.1
US
Eli Lilly and Co
NYSE:LLY
883B USD 16.9 42.8
US
Johnson & Johnson
NYSE:JNJ
553.5B USD 8.8 26.3
CH
Roche Holding AG
SIX:ROG
248.4B CHF 6.3 20.1
UK
AstraZeneca PLC
LSE:AZN
216.3B GBP 6.4 28
US
Merck & Co Inc
NYSE:MRK
270.2B USD 5.7 14.8
CH
Novartis AG
SIX:NOVN
216.3B CHF 7.4 20.7
IE
Endo International PLC
LSE:0Y5F
244.4B USD 160.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 5.2 11.8
US
Pfizer Inc
NYSE:PFE
151.8B USD 4.2 19.5
US
Bristol-Myers Squibb Co
NYSE:BMY
122B USD 4.4 17.3
P/E Multiple
Earnings Growth PEG
KR
C
Celltrion Pharm Inc
KOSDAQ:068760
Average P/E: 26.5
64.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.8
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.3
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28
25%
1.1
US
Merck & Co Inc
NYSE:MRK
14.8
14%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.8
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.5
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17.3
16%
1.1

Market Distribution

Higher than 78% of companies in Korea
Percentile
78th
Based on 1 175 companies
78th percentile
15.5
Low
0 — 2.7
Typical Range
2.7 — 10.1
High
10.1 —
Distribution Statistics
Korea
Min 0
30th Percentile 2.7
Median 5.4
70th Percentile 10.1
Max 19 609.2

Celltrion Pharm Inc
Glance View

Market Cap
2.5T KRW
Industry
Pharmaceuticals

In the bustling world of pharmaceuticals, Celltrion Pharm Inc. has carved a niche for itself, leveraging innovation and strategic market positioning. Born out of South Korea, this dynamic player operates with a vision to transform the pharmaceutical landscape, particularly through its expertise in biosimilars and small molecule drugs. By focusing on cutting-edge research and development, Celltrion Pharm is able to produce high-quality, cost-effective alternatives to branded biologics, which are essential for treating diseases such as cancer and autoimmune disorders. With a comprehensive pipeline of biosimilar products, the company effectively taps into a growing demand, driven by global healthcare systems seeking cost-efficient therapeutics amidst rising healthcare expenditures. Celltrion Pharm's operational strategy extends beyond product innovation. It encompasses robust manufacturing infrastructure and a global distribution network that underscores its financial growth. By owning state-of-the-art production facilities, the company ensures both the scale and quality required to meet international benchmarks, which is pivotal in the highly regulated pharmaceutical industry. Furthermore, strategic alliances and partnerships bolster its market reach, ensuring that its products have strong footholds not just locally, but globally. Through these multifaceted endeavors—ranging from R&D to distribution—the company has positioned itself as a formidable force, achieving sustainable revenue streams by addressing critical healthcare needs and optimizing drug accessibility worldwide.

Intrinsic Value
25 822.63 KRW
Overvaluation 54%
Intrinsic Value
Price ₩56 100
C
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett